Skip to content

EV / sales at other companies

Charles River Laboratories logo
Charles River LaboratoriesCRL
2.8×+0.2×
Bio-Rad Laboratories logo
Bio-Rad LaboratoriesBIO
3.1×+0.1×
Pacific Biosciences of California logo
Pacific Biosciences of CaliforniaPACB
2.5×+0.2×
iRadimed logo
iRadimedIRMD
8.2×+0.6×
Ginkgo Bioworks logo
Ginkgo BioworksDNA
4.3×+2.5×
West Pharmaceutical Services logo
West Pharmaceutical ServicesWST
5.5×0.0×

Other financials

Income statement

See full
Revenue$8.0M+11.1%
Gross profit$371.0K-8.2%
Operating income-$13.9M-18.8%
Net income-$14.3M-26.7%
EPS (diluted)-$0.31-19.2%

Balance sheet

See full
Cash & equivalents$14.1M-26.8%
Total debt$23.8M+301%
Total equity$20.4M-68.9%
Total assets$62.4M-27.0%

Cash flow

See full
Operating cash flow-$15.1M-66.1%
CapEx$394.0K+23.5%
Free cash flow-$15.5M-64.7%

Valuation

See full
Market cap$86.19M-43.8%
Enterprise value$95.86M-31.7%
P/S2.5×-2.6×

Profitability

See full
Operating margin-144.2%-12.7pp
Net margin-145.8%-5.0pp
FCF margin-110.5%-14.9pp

Returns & leverage

See full
Return on equity-116.7%-620pp
Debt / equity1.2×+1.1×
Current ratio2.6×-2.0×

Where this comes from

Calculated from Rapid Micro Biosystems’s reported figures.

Based on the most recent quarter.

The official record: Rapid Micro Biosystems’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →

Ask your AI about Rapid Micro Biosystems's ev / sales.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Rapid Micro Biosystems's EV / sales?
Rapid Micro Biosystems (RPID) reported EV / sales of 3.3× in Q1 2026.
How has Rapid Micro Biosystems's EV / sales changed year-over-year?
Rapid Micro Biosystems's EV / sales decreased by 3.5% year-over-year, from 3.4× to 3.3×.
What is the long-term trend for Rapid Micro Biosystems's EV / sales?
Over 3 years (2022 to 2025), Rapid Micro Biosystems's EV / sales has grown at a 33.9% compound annual growth rate (CAGR), from 1.6× to 3.9×.
What does EV / sales mean?
Enterprise value at the quarter end divided by trailing-twelve-month revenue. A capital-structure-neutral revenue multiple, useful when earnings are negative.